Is Clearmind Medicine Stock a Good Investment?
Clearmind Medicine Investment Advice | CMND |
- Examine Clearmind Medicine's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Clearmind Medicine's leadership team and their track record. Good management can help Clearmind Medicine navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Clearmind Medicine's business and its evolving consumer preferences.
- Compare Clearmind Medicine's performance and market position to its competitors. Analyze how Clearmind Medicine is positioned in terms of product offerings, innovation, and market share.
- Check if Clearmind Medicine pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Clearmind Medicine's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Clearmind Medicine Common stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Clearmind Medicine Common is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Clearmind Medicine Stock
Researching Clearmind Medicine's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 16.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.68. Some equities with similar Price to Book (P/B) outperform the market in the long run. Clearmind Medicine Common recorded a loss per share of 1.23. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 28th of November 2023.
To determine if Clearmind Medicine is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Clearmind Medicine's research are outlined below:
| Clearmind Medicine had very high historical volatility over the last 90 days | |
| Clearmind Medicine may become a speculative penny stock | |
| Clearmind Medicine has a very high chance of going through financial distress in the upcoming years | |
| Clearmind Medicine Common currently holds 3.61 M in liabilities. Clearmind Medicine Common has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Clearmind Medicine's use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (6.23 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Clearmind Medicine Common currently holds about 1.65 K in cash with (4.56 M) of positive cash flow from operations. |
Know Clearmind Medicine's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Clearmind Medicine is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Clearmind Medicine Common backward and forwards among themselves. Clearmind Medicine's institutional investor refers to the entity that pools money to purchase Clearmind Medicine's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Gotham Asset Management, Llc | 2024-09-30 | 339 K | Advisorshares Investments, Llc | 2024-09-30 | 170.6 K | Ubs Group Ag | 2024-09-30 | 141.3 K | Cornerstone Wealth Group, Llc | 2024-09-30 | 20 K | Citadel Advisors Llc | 2024-09-30 | 17.7 K | Hrt Financial Llc | 2024-09-30 | 12.8 K | Royal Bank Of Canada | 2024-09-30 | 569 | Susquehanna International Group, Llp | 2024-06-30 | 0.0 | Geode Capital Management, Llc | 2024-09-30 | 0.0 |
Clearmind Medicine's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.41 M.Market Cap |
|
Clearmind Medicine's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.24) | (3.41) | |
| Return On Capital Employed | (14.07) | (13.37) | |
| Return On Assets | (3.18) | (3.34) | |
| Return On Equity | (10.08) | (9.58) |
Determining Clearmind Medicine's profitability involves analyzing its financial statements and using various financial metrics to determine if Clearmind Medicine is a good buy. For example, gross profit margin measures Clearmind Medicine's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Clearmind Medicine's profitability and make more informed investment decisions.
Please note, the presentation of Clearmind Medicine's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Clearmind Medicine's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Clearmind Medicine's management manipulating its earnings.
Evaluate Clearmind Medicine's management efficiency
Clearmind Medicine Common has return on total asset (ROA) of (0.5795) % which means that it has lost $0.5795 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.679) %, meaning that it created substantial loss on money invested by shareholders. Clearmind Medicine's management efficiency ratios could be used to measure how well Clearmind Medicine manages its routine affairs as well as how well it operates its assets and liabilities. As of December 10, 2024, Return On Tangible Assets is expected to decline to -3.41. The current year's Return On Capital Employed is expected to grow to -13.37. At present, Clearmind Medicine's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 224.1 K, whereas Other Current Assets are forecasted to decline to about 106.1 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.18 | 3.02 | |
| Tangible Book Value Per Share | 2.80 | 2.66 | |
| Enterprise Value Over EBITDA | 0.42 | 0.40 | |
| Price Book Value Ratio | 0.49 | 0.51 | |
| Enterprise Value Multiple | 0.42 | 0.40 | |
| Price Fair Value | 0.49 | 0.51 | |
| Enterprise Value | 394.5 K | 414.2 K |
Leadership effectiveness at Clearmind Medicine Common is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta (1.51) |
Basic technical analysis of Clearmind Stock
As of the 10th of December, Clearmind Medicine shows the mean deviation of 3.69, and Risk Adjusted Performance of 0.0232. Clearmind Medicine Common technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Clearmind Medicine Common downside deviation, treynor ratio, expected short fall, as well as the relationship between the variance and potential upside to decide if Clearmind Medicine Common is priced correctly, providing market reflects its regular price of 1.33 per share. Given that Clearmind Medicine is a hitting penny stock territory we recommend to closely look at its total risk alpha.Understand Clearmind Medicine's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Clearmind Medicine's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0232 | |||
| Market Risk Adjusted Performance | (0.38) | |||
| Mean Deviation | 3.69 | |||
| Semi Deviation | 4.17 | |||
| Downside Deviation | 4.55 | |||
| Coefficient Of Variation | 5034.09 | |||
| Standard Deviation | 6.03 | |||
| Variance | 36.32 | |||
| Information Ratio | (0.0008) | |||
| Jensen Alpha | 0.1422 | |||
| Total Risk Alpha | (0.85) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | (0.39) | |||
| Maximum Drawdown | 45.83 | |||
| Value At Risk | (7.69) | |||
| Potential Upside | 8.13 | |||
| Downside Variance | 20.72 | |||
| Semi Variance | 17.41 | |||
| Expected Short fall | (4.80) | |||
| Skewness | 2.58 | |||
| Kurtosis | 13.69 |
| Risk Adjusted Performance | 0.0232 | |||
| Market Risk Adjusted Performance | (0.38) | |||
| Mean Deviation | 3.69 | |||
| Semi Deviation | 4.17 | |||
| Downside Deviation | 4.55 | |||
| Coefficient Of Variation | 5034.09 | |||
| Standard Deviation | 6.03 | |||
| Variance | 36.32 | |||
| Information Ratio | (0.0008) | |||
| Jensen Alpha | 0.1422 | |||
| Total Risk Alpha | (0.85) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | (0.39) | |||
| Maximum Drawdown | 45.83 | |||
| Value At Risk | (7.69) | |||
| Potential Upside | 8.13 | |||
| Downside Variance | 20.72 | |||
| Semi Variance | 17.41 | |||
| Expected Short fall | (4.80) | |||
| Skewness | 2.58 | |||
| Kurtosis | 13.69 |
Consider Clearmind Medicine's intraday indicators
Clearmind Medicine intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Clearmind Medicine stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 5375.5 | |||
| Daily Balance Of Power | (0.77) | |||
| Rate Of Daily Change | 0.93 | |||
| Day Median Price | 1.38 | |||
| Day Typical Price | 1.36 | |||
| Price Action Indicator | (0.1) | |||
| Period Momentum Indicator | (0.10) |
Clearmind Stock media impact
Far too much social signal, news, headlines, and media speculation about Clearmind Medicine that are available to investors today. That information is available publicly through Clearmind media outlets and privately through word of mouth or via Clearmind internal channels. However, regardless of the origin, that massive amount of Clearmind data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Clearmind Medicine news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Clearmind Medicine relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Clearmind Medicine's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Clearmind Medicine alpha.
Clearmind Medicine Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Clearmind Medicine can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Clearmind Medicine Corporate Management
| BCom BComm | CFO Director | Profile | |
| Mylene Touboul | Accounting Manager | Profile | |
| Gilad Babchuk | Head Communication | Profile | |
| Adi Varon | Controller | Profile | |
| Pr Haden | Vice Development | Profile | |
| Pr MSW | Vice Development | Profile | |
| Adi ZuloffShani | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearmind Medicine Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearmind Medicine. If investors know Clearmind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearmind Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.23) | Return On Assets (0.58) | Return On Equity (2.68) |
The market value of Clearmind Medicine Common is measured differently than its book value, which is the value of Clearmind that is recorded on the company's balance sheet. Investors also form their own opinion of Clearmind Medicine's value that differs from its market value or its book value, called intrinsic value, which is Clearmind Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearmind Medicine's market value can be influenced by many factors that don't directly affect Clearmind Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Clearmind Medicine's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Clearmind Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearmind Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.